Lassa Fever
14
3
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
83.3%
-3.3% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
DMID 23-0015; Lassa Fever CVD 1000
ARN-75039 Lassa Fever Treatment in West Africa
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
LAssa Fever Adjunct Treatment With DEXamethasone
Lassa Fever Clinical Course and Prognostic Factors in Nigeria
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities